Mankind Pharma Limited

Mankind Pharma to close wholly owned subsidiary in Sri Lanka due to regulatory changes.

Mankind Pharma's Board approved the closure of its Sri Lankan wholly owned subsidiary due to regulatory changes. The subsidiary had no business operations and is not material. The board meeting concluded on April 13, 2026.

Mankind Pharma Files Certificate under SEBI (Depositories and Participants) Regulations, 2018 for Q4 FY26

Mankind Pharma Limited submitted a certificate for the quarter ended March 31, 2026, confirming no share dematerialisation or rematerialisation requests were received by its registrar, KFin Technologies Limited, during the period.

Mankind Pharma Acquires Rivotril Brand for India, Bolstering CNS Portfolio

Mankind Pharma acquired the Rivotril brand from Roche for India, gaining exclusive rights to manufacture, market, and distribute clonazepam. This move strengthens Mankind's focus on chronic CNS therapies and complements its existing neuro portfolio, with plans for line extensions.

Mankind Pharma Wins CGST Appeals Case, Penalty of ₹1.02 Crore Dropped

Mankind Pharma Limited announced it received an Order-in-Appeal from CGST (Appeals), Meerut, on February 25, 2026. The order drops a penalty of ₹1.02 crore imposed earlier. This ruling pertains to the financial years 2017-18 to 2020-21.

Mankind Pharma: ICRA Reaffirms Credit Ratings for NCDs and Fund-Based Limits

Mankind Pharma's credit ratings were reaffirmed by ICRA Limited on February 24, 2026. The rating for Non-Convertible Debentures of ₹5,000 crore was reaffirmed as (ICRA) AA+/Stable. Long-term/short-term fund-based limits of ₹1,250 crore were also reaffirmed.

Mankind Pharma to Participate in Chasing Growth 2026 Investor Conference on Feb 24

Mankind Pharma Limited will attend the "Chasing Growth 2026" Investor Conference in Mumbai on February 24, 2026. Management will conduct one-on-one and group meetings. No unpublished price-sensitive information will be shared.

Mankind Pharma Wins GST Appeal, Penalty of ₹46.32 Lakhs Dropped

Mankind Pharma Limited received a favorable order on February 16, 2026, from the Joint Commissioner of State Tax, Nagpur. The appeal against a penalty of ₹46,32,582 imposed under the CGST Act, 2017, has been dropped. This pertains to the financial year 2020-21.

Mankind Pharma Subsidiary BSV Undergoes GST Search/Inspection from Feb 3-8, 2026

Mankind Pharma's subsidiary, Bharat Serums and Vaccines Limited (BSV), was subject to a Goods & Service Tax search and inspection from February 3 to February 8, 2026. BSV fully cooperated with authorities. The company stated there is no material impact on BSV's financials or operations.

Mankind Pharma Q3 FY26 Earnings Call Transcript Released

Mankind Pharma's Q3 FY26 revenue rose 11.5% YoY to ₹3,567 crore, with adjusted EBITDA at 25.9%. 9M FY26 revenue increased 18.7% to ₹10,835 crore. Domestic revenue grew 11.1% in Q3. Chronic therapies like cardio and antidiabetic showed strong momentum. The transcript of the Q3 FY26 earnings call is now available.

Mankind Pharma Q3 FY26 Unaudited Results: Consolidated Revenue ₹3,567 Cr, PAT ₹414 Cr

Mankind Pharma reported Q3 FY26 consolidated revenue of ₹3,567.20 crore and profit after tax of ₹413.88 crore. Standalone revenue was ₹2,632.68 crore with profit after tax of ₹449.47 crore. The Board approved the results on February 3, 2026.

Mankind Pharma to Participate in Two Investor Conferences in February 2026

Mankind Pharma Limited announced its participation in two investor conferences in February 2026. The company will attend the MANTHAN – Systematix India Annual Flagship Conference on February 9, 2026, and the Advantage India - Axis Capital's Flagship India Conference on February 10, 2026, both in Mumbai.

Mankind Pharma Q3 FY26 Earnings Call Audio Recording Available

Mankind Pharma Limited has released the audio recording of its Q3 & 9M FY26 investor conference call. The call was held on February 3, 2026, and featured senior management. The recording is available on the company's website.

Mankind Pharma Q3FY26 Results: Standalone Profit at ₹449.47 Crore

Mankind Pharma reported unaudited standalone results for Q3FY26. Revenue from operations reached ₹2,632.68 crore, with a profit after tax of ₹449.47 crore. For the nine months ended December 31, 2025, revenue was ₹7,839.36 crore and profit after tax was ₹1,329.04 crore. Key ratios include a debt-equity ratio of 0.40 and a net profit margin of 17%.

Mankind Pharma Q3FY26 Revenue Jumps 11.5% to ₹10,835 Crore; Adj. EBITDA Margins at 25.9%

Mankind Pharma reported Q3FY26 revenue of ₹3,567 crore (up 11.5% YoY) and 9MFY26 revenue of ₹10,835 crore (up 18.7% YoY). Adjusted EBITDA margins stood at 25.9%. Domestic business grew 11.1% YoY, with strong performance in chronic therapies. Consumer Healthcare revenue increased 5.2% YoY.

Mankind Pharma Q3FY26 Revenue Up 11.5% to ₹3,567 Crore; Adj. EBITDA Margin at 25.9%

Mankind Pharma reported Q3FY26 revenue of ₹3,567 Crore, up 11.5% YoY. Adjusted EBITDA margin was 25.9%. Domestic revenue grew 11.1% to ₹3,046 Crore. For 9M FY26, revenue rose 18.7% to ₹10,835 Crore. An earnings concall is scheduled for February 3, 2026.

Mankind Pharma Q3FY26 Results: Standalone Revenue ₹2,632.68 Cr, Net Profit ₹449.47 Cr

Mankind Pharma reported Q3FY26 standalone revenue of ₹2,632.68 crore and net profit of ₹449.47 crore. For the nine months ended December 31, 2025, standalone revenue was ₹7,839.36 crore with a net profit of ₹1,329.04 crore. The company's Board of Directors approved these unaudited financial results on February 3, 2026.

Mankind Pharma: ICRA Withdraws ₹1,500 Cr Commercial Paper Rating

Mankind Pharma Limited announced that ICRA Limited has withdrawn the credit rating for its ₹1,500 crore Commercial Paper, effective January 16, 2026. The company's other outstanding ratings, including ₹5,000 crore in Non-Convertible Debentures and ₹1,250 crore in fund-based limits, remain unchanged.

Mankind Pharma to Host Investor Call on Feb 3 for Q3 & 9M FY26 Results

Mankind Pharma Limited will host an investor conference call on February 3, 2026, at 6:00 PM IST to discuss Q3 and 9M FY26 results. Key management personnel, including the MD and CEO, will participate. Dial-in details and pre-registration are available.

Mankind Pharma: Certificate under SEBI Regulations for Q3 FY26

Mankind Pharma Limited received a certificate from its RTA, KFin Technologies, for the quarter ended December 31, 2025. No share dematerialisation or rematerialisation requests were processed during this period.

Mankind Pharma: Trading Window Closed Jan 1, 2026, for Q3 FY26 Results

Mankind Pharma's trading window will be closed from January 01, 2026. This closure is linked to the upcoming declaration of unaudited financial results for the quarter and nine months ending December 31, 2025. The exact date of the board meeting for results approval will be announced later.

Mankind Pharma receives GST order, expects no material financial impact.

Mankind Pharma received a GST order levying a penalty of ₹15.32 crore for FY19-23. The company disputes the order, citing reconciliation differences in GST returns, and expects no material financial or operational impact. An appeal will be filed.

Mankind Pharma Receives ESG Rating of '71' from NSE Sustainability

Mankind Pharma received an ESG rating of 71 from NSE Sustainability for FY25, based on publicly available information. The company did not solicit this rating.

Mankind Pharma Receives ESG Rating of '64.8' (Grade B) from SES

Mankind Pharma received an ESG Rating of '64.8' (Grade B) from SES ESG Research for FY 2024-25, based on publicly available data. The company did not commission the rating.

Mankind Pharma Receives GST Order for FY19 & FY20

Mankind Pharma received a GST order with a penalty of ₹22.16 lakh for FY19 & FY20. The company will appeal and anticipates no material financial impact.

Mankind Pharma Receives Order from CGST, Haryana; to Appeal

Mankind Pharma received an order from CGST, Haryana, with a penalty of ₹83.01 lakh for FY 2021-22. The company will appeal, citing the order as arbitrary and without material financial impact.

Mankind Pharma withdraws ₹3,500 crore Commercial Paper rating; other ratings remain outstanding

Mankind Pharma withdrew the credit rating for ₹3,500 crore Commercial Paper. Other ratings, including ₹5,000 crore Non-Convertible Debentures (ICRA AA+/Stable), remain outstanding as of November 13, 2025.

Mankind Pharma to participate in Avendus Spark INDX Conference on 18 Nov 2025

Mankind Pharma to participate in Avendus Spark INDX 2025 conference in Mumbai on November 18, 2025, involving one-on-one and group meetings. No unpublished price-sensitive information will be shared.

Mankind Pharma Reports Q2 & H1 FY26 Results and Releases Concall Transcript

Mankind Pharma released its Q2 & H1 FY26 concall transcript. Revenue grew 21% to ₹3,697 crore, but PAT declined 21.3%. Domestic business faced GST and monsoon impacts. Management expects H2 recovery.

Mankind Pharma to Attend Anand Rathi Annual Flagship Conference on November 12, 2025

Mankind Pharma will participate in the Anand Rathi Annual Flagship Conference on November 12, 2025, in Mumbai for investor meetings. No unpublished price sensitive information will be shared.

Mankind Pharma Announces Unaudited Financial Results for Quarter and Half Year Ended September 30, 2025

Mankind Pharma announces unaudited financial results for the quarter and half year ended September 30, 2025, with consolidated revenue of ₹3,697.16 crore and profit before tax of ₹624.02 crore for the quarter.

Mankind Pharma Approves Unaudited Standalone and Consolidated Results for Quarter Ended September 30, 2025

Mankind Pharma's board approved unaudited standalone and consolidated financial results for the quarter ended September 30, 2025. Standalone revenue from operations was ₹2,608.78 crore and profit was ₹458.90 crore.

Mankind Pharma releases audio recording of Q2 & H1 FY26 Investor Conference Call

Mankind Pharma has released the audio recording of its Investor Conference Call for Q2 & H1 FY26, held on November 6, 2025, on its website.

Mankind Pharma Investor Presentation on Q2FY26 Financial Results

Mankind Pharma releases investor presentation for Q2FY26, showcasing a 20.8% YoY increase in revenue, driven by domestic and export growth, but a decline in PAT. Management expects growth recovery in H2.

Mankind Pharma Approves Unaudited Standalone & Consolidated Results for Quarter Ended Sep 30, 2025

Mankind Pharma board approves unaudited standalone and consolidated financial results for quarter ended September 30, 2025. Meeting held on November 6, 2025.

Mankind Pharma Q2FY26 Revenue Up 20.8% YoY, EBITDA Margin at 25.0%

Mankind Pharma's Q2FY26 revenue rose 20.8% YoY to ₹3,697 crore, with a 25.0% EBITDA margin. Domestic revenue increased by 14.5%, while exports grew significantly by 82.6%. Earning concall on 06th November, 2025.

Mankind Pharma to participate in Avendus Spark Annual Investor Conference on November 12, 2024

Mankind Pharma will attend Avendus Spark's Annual Investor Conference on November 12, 2024, in Mumbai, assuring no UPSI will be shared.

Mankind Pharma Receives 'B' ESG Rating from MSCI

Mankind Pharma received a 'B' ESG rating from MSCI on November 4, 2025. The report was issued independently. This disclosure is per Regulations 30 and 51 of the Listing Regulations.

Mankind Pharma receives unsolicited ESG rating score of '69'

Mankind Pharma received an unsolicited ESG rating score of '69' from CFC Finlease Private Limited on October 29, 2025. The full report is available on a paid basis.

Mankind Pharma: CRISIL Reaffirms and Withdraws Credit Ratings for Various Instruments

CRISIL Ratings reaffirmed 'AA+/Stable' for NCDs and 'A1+' for Commercial Paper (reduced from ₹5,000 crore to ₹1,500 crore), while withdrawing ratings for ₹1,250 crore bank loan facilities.

Mankind Pharma Announces Investor Conference Call for Q2 & H1 FY26

Mankind Pharma is hosting an investor call on November 6, 2025, at 6 PM IST to discuss Q2 & H1 FY26 results. Senior management will be present.

Mankind Pharma acquires Bharat Serums & Vaccines' Women Health Rx Portfolio for ₹797 Crores

Mankind Pharma acquired Bharat Serums & Vaccines' Women Health Rx Portfolio for ₹797 Crores, strengthening its position in the women's health segment through a strategic slump sale.

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Mankind Pharma received a certificate from KFin Technologies confirming compliance with SEBI regulations regarding dematerialisation/rematerialisation requests for the quarter ended September 30, 2025.

Mankind Pharma's ₹ 2.91 Crore GST Penalty Withdrawn on Appeal

MANKIND Receives Approval for Re-classification of Ayushi and Poonam Estates LLP

Mankind Pharma to attend Eleventh Edition of the Ashwamedh, Elara India Dialogue

Mankind Pharma to attend 21st Annual Global Investor Conference in Mumbai

Mankind Pharma receives 'adequate' Crisil ESG 57 rating for FY25

Mankind Pharma incorporates wholly owned subsidiary in Russia

Mankind Pharma's 34th AGM: Approvals and Director Re-appointment

Mankind Pharma Sees Strong Q1 FY26 Revenue Growth, Drives BSV Integration & Strategic Progress